About pemigatinib
Fibroblast growth factor receptor inhibitor
Used for
- Treats previously treated bile duct cancer with an FGFR2 fusion or rearrangement.
- Treats certain blood cancers with an FGFR1 rearrangement.
Usual adult dose
Bile duct cancer: 13.5 mg by mouth once daily for 14 days, then 7 days off. FGFR1-rearranged blood cancer: 13.5 mg once daily continuously.
Common side effects
- High phosphate levels
- Nail and skin changes
- Diarrhea
- Eye problems, including retinal detachment
Important warnings
- Eye examinations are needed before and during treatment.
- High phosphate levels can cause soft-tissue mineral buildup.
- Report vision changes promptly.
- May harm an unborn baby; use effective contraception during treatment and afterward.
Pregnancy
May cause fetal harm. Avoid pregnancy during treatment and for one week after the last dose.
Breastfeeding
Do not breastfeed during treatment and for one week after the last dose.
Interactions
- Strong or moderate CYP3A inhibitors may increase pemigatinib exposure.
- Strong or moderate CYP3A inducers may reduce pemigatinib exposure.
- Acid-reducing medicines can affect absorption; separate antacids by two hours before or after.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.